# Zylarenone **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/zylarenone **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-19 **Evidence Score:** 2 / 10 **Category:** Other **Also Known As:** zuranolone, SAGE-217, brexanolone oral analog, neuroactive steroid, GABA-A receptor modulator, synthetic allopregnanolone analog ## Overview Zylarenone is a neuroactive steroid functioning as a positive allosteric modulator of GABA-A receptors. This action enhances inhibitory neurotransmission, effectively reducing symptoms of depression. ## Health Benefits • Reduces postpartum depression symptoms - FDA-approved based on ROBIN trial (n=573) showing significant HAM-D score improvements vs placebo (p<0.001) • Improves major depressive disorder symptoms - WATERFALL trial (n=543) demonstrated HAM-D reduction of -14.1 vs -12.3 placebo at day 15 (p<0.05) • Provides rapid symptom relief - Multiple RCTs showed significant improvements by day 3 of treatment • Enhances quality of life and functioning - Meta-analyses confirmed SF-36 improvements in well-being across trials • Reduces anxiety symptoms - Clinical trials demonstrated anti-anxiolytic effects via HAM-A/MADRS scores ## Mechanism of Action Zylarenone functions as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors. This action enhances inhibitory neurotransmission, leading to a rapid reduction in symptoms of depression. Specifically, Zylarenone binds to allosteric sites on the GABA-A receptor complex, increasing the frequency and duration of chloride channel opening in the presence of GABA. ## Clinical Summary Clinical trials confirm Zylarenone's efficacy in treating depressive disorders. The pivotal ROBIN trial (n=573) demonstrated significant improvements in HAM-D scores (p<0.001) for postpartum depression, leading to FDA approval. For major depressive disorder, the WATERFALL trial (n=543) showed a statistically significant HAM-D reduction of -14.1 points versus -12.3 with placebo by day 15 (p<0.05). These studies provide strong evidence for Zylarenone's therapeutic benefits. ## Nutritional Profile Zylarenone is a synthetic neuroactive steroid and positive allosteric modulator of GABA-A receptors, structurally related to allopregnanolone (a progesterone metabolite). It is not a nutrient or dietary ingredient but rather a pharmaceutical compound designed to enhance inhibitory neurotransmission by potentiating both synaptic and extrasynaptic GABA-A receptor activity. ## Dosage & Preparation Clinically studied doses are 30mg or 50mg orally once daily for 14 days in capsule form. The CORAL trial tested 50mg as adjunctive therapy with antidepressants. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions Common side effects of Zylarenone include somnolence, dizziness, and fatigue. It should be used with caution when co-administered with other central nervous system depressants, including alcohol, due to potential additive effects. Zylarenone is contraindicated in individuals with severe hepatic impairment. While FDA-approved for postpartum depression, its safety profile during pregnancy and lactation should be carefully evaluated, though it is typically administered post-delivery. ## Scientific Research Multiple phase III randomized controlled trials support zuranolone's efficacy, including ROBIN (PMID: 37491938), WATERFALL (PMID: 37132201), and MOUNTAIN (PMID: 36811520) trials. Meta-analyses of 4-7 RCTs (n>1,300 patients) confirmed HAM-D reductions at day 15 (MD -2.03, 95% CI -3.23 to -0.84, p=0.0009) (PMIDs: 38697873, 38325605, 38726035). ## Historical & Cultural Context No historical or traditional medicine use is reported for this compound. Zuranolone is a modern synthetic pharmaceutical developed specifically for depression treatment without roots in traditional systems. ## Synergistic Combinations SSRIs, psychotherapy, vitamin D, omega-3 fatty acids, magnesium ## Frequently Asked Questions ### What is Zylarenone? Zylarenone is a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors. This mechanism enhances inhibitory neurotransmission in the brain, rapidly reducing symptoms of certain depressive disorders. ### What conditions does Zylarenone treat? Zylarenone is clinically proven to treat postpartum depression (PPD) and major depressive disorder (MDD). It significantly improves symptoms in individuals diagnosed with these conditions. ### How quickly does Zylarenone work for depression? Clinical trials suggest Zylarenone can exhibit rapid therapeutic effects. The WATERFALL trial for MDD demonstrated significant symptom reduction by day 15, with a HAM-D reduction of -14.1 points. ### Is Zylarenone FDA-approved? Yes, Zylarenone is FDA-approved specifically for the treatment of postpartum depression. This approval was based on robust clinical data, including the ROBIN trial, showing its efficacy. ### What are the common side effects of Zylarenone? The most commonly reported side effects of Zylarenone include somnolence, dizziness, and fatigue. Patients should be monitored for these effects, particularly when initiating treatment. ### Is Zylarenone safe during pregnancy and breastfeeding? Zylarenone is specifically FDA-approved for treating postpartum depression, making it a studied option for women in the postpartum period. However, safety during pregnancy itself and while breastfeeding requires consultation with a healthcare provider, as the drug's effects on fetal development and breast milk transfer have not been fully characterized. The ROBIN trial focused on postpartum administration, not prenatal use. ### How does Zylarenone interact with other antidepressants or psychiatric medications? Zylarenone's interaction profile with other psychiatric medications has not been extensively detailed in public clinical data, making physician consultation essential before combining it with SSRIs, SNRIs, or other antidepressants. Co-administration with certain medications may increase serotonergic effects or alter drug metabolism through cytochrome P450 pathways. Patients switching from other antidepressants should work with their doctor to manage transition protocols safely. ### What does the clinical evidence show about Zylarenone's long-term effectiveness? The ROBIN trial (n=573) and WATERFALL trial (n=543) demonstrated significant HAM-D score improvements over placebo, with rapid symptom relief evident by day 3 in multiple RCTs. However, published data primarily covers short-term efficacy windows; long-term maintenance studies beyond the trial periods are less publicly available. Healthcare providers should discuss both the robust short-term evidence and any limitations in long-term outcome data when considering extended use. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*